REVB
What one share of Revelation Biosciences holds
Pharmaceutical Preparations
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (“AKI”) and GEM-CKD as a treatment for chronic kidney disease (“CKD”).
Revelation Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$8.31 |
|---|---|
| Cash and investments | $2.94 |
| Book value | $2.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$2.71 | — | −$0.36 | — | $7.50 |
| 2021 | — | −$170.00 | $1.87 | −$159.17 | — | −$1.41 |
| 2022 | — | −$596.79 | — | −$618.28 | — | $54.41 |
| 2024 | — | −$1,052 | $1.34 | −$1,283 | — | — |
| 2025 | — | −$23.95 | — | −$13.32 | — | $5.59 |